St. Jude Medical: Cardiac Rhythm Management Business Has “Turned The Corner”
This article was originally published in The Gray Sheet
Executive Summary
The firm reported during its second-quarter earnings call that its cardiac rhythm management business has stabilized after several quarters of market share decline.
You may also be interested in...
Medtronic, St. Jude Launch New Quadripolar Devices
Medtronic has launched two more Attain Performa left ventricular quadripolar leads for the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators following FDA approval announced Dec. 11. On the same day, St. Jude announced CE mark of the Quadra Allure MP cardiac resynchronization therapy pacemaker, the first quadripolar CRT-P with MultiPoint pacing.
Recalled ICD Leads Can Be Extracted Safely, Cleveland Clinic Study Shows
A 10-year retrospective study from the Cleveland Clinic shows that implantable cardioverter defibrillator leads subject to recalls can be extracted with the same safety and efficacy as non-recalled ICD leads. Another study, published in the same issue of Heart Rhythm, found that younger age and female sex are independent predictors of failure for St. Jude’s Riata lead.
St. Jude First To Market Leadless Pacemaker With Nanostim Buy
St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.